eSpeed settles patent dispute with CBOT and CME

eSpeed, a subsidiary of interdealer broker Cantor Fitzgerald and developer of electronic trading technology, has settled its lawsuit against the Chicago Mercantile Exchange (CME) and the Chicago Board of Trade (CBOT) over infringement on patented technology for electronic exchange trading. The CME and the CBOT each agreed to pay eSpeed $15 million in installments over the next five years.

As part of the agreement, all companies will be released from the legal claims brought against each other without admitting liability, a statement issued by the CME and the CBOT said.

At issue in the suit was whether the CME and the CBOT had infringed upon a patent purchased by eSpeed in April 2001 from Electronic Trading Systems for $3 million in stock and cash. The technology is involved in an electronic automated futures order matching system.

Electronic Trading Systems had already filed suit against the Chicago exchanges for infringement prior to the technology's sale to eSpeed. eSpeed assumed the role of plaintiff through the purchase.

Several other exchanges have been concerned with the technology at issue between the former litigants. In April, eSpeed reached an agreement with the IntercontinentalExchange, an online electronic market-place particularly strong in energy and metals contracts, to license the technology for $2 million per year and $0.20 per trade.

Meanwhile, a lawsuit between eSpeed and the New York Mercantile Exchange over the same technology is ongoing.

In a statement, eSpeed's chief executive and president Howard Lutnick said: "[We] believe this is just one illustration of the enormous unrealised value of eSpeed's extensive intellectual property portfolio."

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact info@risk.net or view our subscription options here: http://subscriptions.risk.net/subscribe

You are currently unable to copy this content. Please contact info@risk.net to find out more.

Most read articles loading...

You need to sign in to use this feature. If you don’t have a Risk.net account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here